FDA Approves Hovilpri, a New Kind of Herpes Pill for the Hardest Cases
On Oct. 9, the FDA approved Hovilpri (pritelivir), an oral drug for immunocompromised adults whose herpes sores do not respond to standard antivirals. Asahi Kasei says it is the first approved option for these cases with a new mechanism in nearly 30 years.
So basically: The FDA just approved a new herpes pill called Hovilpri. It is not for everyday cold sores. It is for people with weak immune systems whose herpes sores will not heal on the usual drugs. It attacks the virus in a different way than the drugs doctors have used for decades.
Who this is for
Herpes simplex is incredibly common. About 3.8 billion people under 50 carry HSV-1, according to figures cited by the company. For most people it is mild or never shows up at all.
It is a different story for people whose immune systems are weakened. That includes:
- Stem cell and organ transplant patients
- People with blood cancers and other cancers
- People living with HIV
- People with autoimmune or inflammatory diseases
For them, outbreaks can be more frequent, more painful, and last a long time. Sometimes the standard drugs, acyclovir, valacyclovir, and famciclovir, just stop working.
Hovilpri is approved only for those adults, when the sores have not responded to those three drugs.
Why the old drugs fail
The classic herpes drugs need to be switched on by an enzyme the virus makes. If the virus mutates that enzyme, the drug never activates. That is how resistance happens.
Until now, the backup options were mostly IV drugs like foscarnet, which can be hard on the body and usually means time in a hospital or clinic.
How Hovilpri is different
Pritelivir, the drug inside Hovilpri, is a helicase-primase inhibitor. In plain words, it blocks the machinery the virus uses to unzip and copy its DNA. It does not need the virus’s enzyme to turn on, so that common resistance trick does not stop it.
It is also a pill, taken once a day after a bigger first dose. No IV needed.
Asahi Kasei, the Japanese company that now owns it, says it is the first FDA approved treatment for these hard cases with a new mechanism in nearly 30 years. The drug was developed by Aicuris, a German company Asahi Kasei bought in April.
The trial results
The approval is based on a Phase 3 trial of 101 immunocompromised adults. Patients got either Hovilpri or their doctor’s choice of older treatments.
- By day 28: all sores healed in 63% of Hovilpri patients, compared to 34% on other treatments
- By day 42: 82% compared to 42%
- Side effects: reported in 22% of Hovilpri patients, compared to 54% on other treatments
- Most common side effect: headache, in 6% of patients
The drug got Breakthrough Therapy and Fast Track designations, plus priority review.
One thing to watch: certain heartburn drugs can lower how much pritelivir the body absorbs, so doctors have to manage that.
What happens next
The company expects Hovilpri to be available in the U.S. before the end of 2026. Reuters reported the company has estimated about 15,000 U.S. patients could use it, with peak sales of more than $400 million a year by the mid to late 2030s.
Why it matters
This is a small group of patients, but they are some of the sickest people in the hospital. A transplant or cancer patient fighting a sore that will not heal is dealing with a lot already.
A pill that works when the old drugs do not, with fewer side effects than the IV options, is a real upgrade.
My take
Herpes drugs have barely changed in my lifetime, so a brand new way of hitting the virus is a bigger deal than it sounds.
I also like that it is a pill. Anything that keeps a sick patient out of an IV chair is a win.
The bigger question for me is what comes next. If this class of drug works this well on the toughest cases, I would love to see it tested for regular outbreaks too.
So basically — pass it on.